Weight loss injections are being considered as potential cancer prevention agents, according to experts who have highlighted a study linking these medications to a decreased risk of obesity-related cancers. Obesity has been associated with a higher likelihood of developing various types of cancer, including breast, bowel, pancreas, kidney, liver, and stomach cancers.
Drugs such as Mounjaro, Wegovy, and Ozempic, known as glucagon-like peptide-1 receptor agonists (GLP-1), are commonly used to manage obesity and type 2 diabetes. Recent research indicates that these drugs may offer broader health benefits beyond their primary treatment purposes.
A study conducted by US researchers examined the use of GLP-1 drugs in over 161,000 obese patients without diabetes or a history of obesity-related cancer. Half of the participants received weight loss injections, while the other half received counseling on diet and exercise. The analysis, published in the Annals of Oncology, revealed that individuals using GLP-1 drugs had a 41% reduced risk of being diagnosed with obesity-related cancers compared to those who did not use the injections.
Dr. Aparna Kamat, the senior author of the study and director of the Division of Gynaecologic Oncology at Houston Methodist Hospital, emphasized that GLP-1 drugs were significantly associated with lower cancer incidence directly linked to excess body weight. The study showed a 41% overall reduction in cancer risk, with even greater reductions observed in specific subgroups, such as men and patients with gynaecologic cancers.
However, the study noted that the reduction in cancer risk was not observed among black patients, possibly due to various factors like access to care and biological differences. The research also highlighted that different formulations of GLP-1 drugs varied in their effectiveness, with tirzepatide users experiencing the most significant reduction in obesity-related cancer incidence.
Dr. Kamat stressed that while the findings do not establish a direct causation between GLP-1 drugs and cancer prevention, they provide valuable insights for potential discussions with obese, non-diabetic patients who are candidates for these medications. The study’s second author, Professor Pedro Ramirez, chairman of the Department of Obstetrics and Gynaecology at Houston Methodist Hospital, suggested that further long-term clinical trials are needed to explore the potential cancer prevention benefits of GLP-1 drugs.
In conclusion, the study indicates that GLP-1 drugs could play a vital role in redefining obesity treatment and cancer prevention strategies. Understanding the broader health impact of these medications is crucial as their global usage continues to rise.